DB-1329 / DualityBio - LARVOL DELTA

DB-1329: A novel antibody-drug conjugate targeting CDCP1 demonstrates potent preclinical anti-tumor activity across multiple solid tumors (AACR 2026) - "These compelling preclinical results establish CDCP1-ADC DB-1329 as a promising therapeutic candidate, with potent and targeted anti-tumor efficacy against multiple CDCP1-positive solid malignancies. Our findings strongly support the continued development and clinical translation of CDCP1-ADC."

ADC • Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Solid Tumor • CDCP1 • TOP1